OpenClinica announces that K&L Consulting Services, Inc. (“K&L”) of Fort Washington, Pennsylvania, has selected the OpenClinica Enterprise Edition for Electronic Data Capture (“EDC”) and clinical data management for Phase I-IV clinical trials. K&L is a Contract Research Organization (“CRO”) for clinical trial Sponsors, providing end-to-end services for all types of clinical studies, as well as post-marketing pharmacovigilance support and outcomes research.
K&L is increasing the breadth of its capabilities in the US as well as in Asia and the Pacific region, especially in China. “We welcome this opportunity to work closely with K&L to help them grow their global practice,” said Ben Baumann, Chief Operating Officer at OpenClinica, LLC.
When asked what attracted K&L to OpenClinica Enterprise, Vice President of Biostatistics and Data Management, Dr. Henry Wu said “OpenClinica Enterprise allows us to deploy studies quickly and cost effectively, and pass this value on to our clients.” OpenClinica’s innovative commercial open source model stands out in the realm of clinical research software. The company’s strategy is to leverage its rapidly growing global community of users and developers (currently comprising nearly 17,000 people) in order to produce high quality software in a more agile and transparent way for use across the spectrum of clinical research.
The OpenClinica software is available in two editions: The OpenClinica Community Edition is freely available under a common open source license. The OpenClinica Enterprise Edition pairs the open source technology with a regulatory compliance infrastructure and robust support services. According to Baumann, “OpenClinica’s model allows us to focus on what makes EDC software successful--how it is implemented and supported.”
About K&L Consulting Services, LLC
K&L Consulting Services, Inc. is a Contract Research Organization (“CRO”) offering Data Management, Biostatistics, Statistical Programming and Medical Writing as well as CDISC compliant eSubmission services to the pharmaceutical, biotechnology and medical device industries worldwide. K&L’s services encompass end-to-end solutions utilizing industry data standards and rigorous operating procedures that enhance Clients’ ability to get their products approved faster at minimum risk and lower cost in order to meet patients’ needs for advanced medicines. More information at http://www.klserv.com.
About OpenClinica, LLC
Waltham, Massachusetts-based OpenClinica, LLC enhances the productivity of clinical trials through commercial open source software. With over 1,000 implementations at biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, the OpenClinica software facilitates electronic data capture and data management, increasing the speed of collection and quality of data in clinical trials. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. For more information – including product and source code downloads – visit http://www.openclinica.com or follow @OpenClinica on Twitter.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Making the Grade: Registries as Sources of Regulatory-Grade Real-World Evidence (RWE)
February 13th 2025Dr. Peter Wahl, MLA, MS, ScD, VP and Global Head of Scientific Affairs at CorEvitas, part of the PPD™ clinical research business of Thermo Fisher Scientific, discusses the critical role of protocol-driven registries in generating regulatory grade RWE to serve multiple and evolving evidence needs across the drug development life cycle. He covers key considerations for selecting the right type of registry, the advantages over EMR datasets, and how registry data contextualizes safety and effectiveness to fulfill FDA and EMA post-marketing requirements.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.